Calidi (CLDI) Director Corazon D. Sanders Receives Stock Options

What Happened

• Corazon D. Sanders, a director of Calidi Biotherapeutics (CLDI), was granted 6,000 non‑qualified stock options on August 17, 2026.
• Exercise price: $1.36 per share (equal to the closing price on the grant date). Aggregate exercise cost to buy all shares: $8,160. This filing reports a grant/award (derivative), not a cash purchase or sale.

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 19, 2026 (timely within required reporting window).
• Award type: Non‑qualified stock options issued under the Issuer’s 2023 Equity Incentive Plan and the company’s non‑employee director compensation policy.
• Vesting: 1/12th of the options vest and become exercisable each month over one year starting on the grant date (fully vested after 12 months).
• Shares owned after transaction: Not reported in this filing.
• Footnotes: F1 describes the option grant, exercise price, vesting schedule and plan; F2 notes this grant does not include previously granted options to the reporting person.

Context

• This is a compensation grant to a non‑employee director (common practice) rather than an outright purchase or sale. It creates potential future equity if the director exercises the options and holds or sells the resulting shares.
• Because the exercise price equals market close on the grant date, these options had no intrinsic value at grant (they are at‑the‑money).